Clinical Trial Results Home

Clopidogrel

 Contents
Trials
Clopidogrel Pre-Treatment Studies
Clopidogrel Loading Dose Studies
Platelet Physiology
Genomics
 Trials

ADAPT-DES: A Large-Scale, Multicenter, Prospective, Observational Study of the Impact of Clopidogrel Hyporesponsiveness on Patient Outcomes

     -Trial Overview by Dr. Gregg W. Stone (TCT 2011)

     -Trial Overview by Dr. Gregg W. Stone (AHA 2011)

     -One-Year Results by Dr. Gregg W. Stone (TCT 2012)

ARCTIC: Antiplatelet Treatment Versus a Common Antiplatelet Treatment for DES Implantation

     -A Double Randomization of a Monitoring Adjusted Antiplatelet Treatment Versus a Common Antiplatelet Treatment for DES Implantation, and Interruption Versus Continuation of Double Antiplatelet Therapy by Dr. Jean-Philippe Collet (TCT 2010)

     -Trial Overview by Dr. Gilles Montalescot (AHA 2012)

ARMYDA: Atorvastatin for Reduction of Myocardial Damage During Angioplasty

      -Pretreatment with Atorvastatin Compared with Placebo in Patients Scheduled for Elective PCI on the Risk of Procedural Myocardial Injury by Dr. V. Pasceri, et al. (2004)

 

ARMYDA-150: High Vs. Standard Clopidogrel Maintenance Dose After Percutaneous Coronary Intervention: Effects on Platelet Inhibition, Endothelial Function, and Inflammation

      -Trial Overview by Giuseppe Patti (CRT 2011)

ARMYDA-2: Atorvastatin for Reduction of Myocardial Damage During Angioplasty-2

      -300 mg vs. 600 mg of Plavix During PCI by Dr. Germano Di Sciascio (ACC 2005)

ARMYDA-4: Atorvastatin for Reduction of Myocardial Damage During Angioplasty-4

      -Prospective, Multicenter, Randomized Double-blind Trial Investigating Influence on PCI Outcome of Additional 600 mg Clopidogrel Load in Patients on Chronic Therapy - "ARMYDA-Reload" by Dr. Germano Di Sciascio (TCT 2007)

ARMYDA-5: Atorvastatin for Reduction of Myocardial Damage During Angioplasty-5

      -Prospective, Multicenter, Randomized Trial Investigating Influence on Outcome of in-lab 600 mg Clopidogrel Loading vs. 6-hour Pre-PCI Treatment - "ARMYDA-Preload" by Dr. Germano Di Sciascio (TCT 2007)

 

CHARISMA: Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management and Avoidance

      -Data Interpretation

      -CHARISMA: The "CAPRIE-like" Cohort by Dr. Deepak L. Bhatt

CHARISMA Genomics Substudy: Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management and Avoidance

      -Trial Overview by Dr. Deepak L. Bhatt, et al.

 

COGENT: A Prospective, Randomized, Placebo-Controlled Trial of Omeprazole in Patients Receiving Aspirin and Clopidogrel

      -Results by Dr. Deepak L. Bhatt (TCT 2009)

CREDO: Clopidogrel for the Reduction of Events During Observation

      -Pretreatment Compared with No Pretreatment with Clopidogrel Prior to Elective PCI

CURE & PCI-CURE: Clopidogrel in Unstable Angina to Prevent Recurrent Events & Clopidogrel in Unstable Angina to Prevent Recurrent Ischemic Events in Patients Undergoing Percutaneous Coronary Intervention

      -Results

CURRENT OASIS-7: Clopidogrel Optimal Loading Dose Usage to Reduce Recurrent Events/Optimal Antiplatelet Strategy for Interventions

      -A 2x2 Factorial Randomized Trial of Optimal Clopidogrel and Aspirin Dosing in Patients with ACS Undergoing an Early Invasive Strategy with Intent for PCI by Dr. Shamir R. Mehta

 

Effect of Proton Pump Inhibitors on Clinical Outcome in Patients Treated with Clopidogrel:

      -A Meta-Analysis by Dr. Jolanta Siller-Matula (TCT 2010)

 

HOST-ASSURE: Randomized Trial: Adjunctive Cilostazol Versus Double Dose Clopidogrel after PCI with Drug Eluting Stent

      -Trial Overview by Dr. Hyo-Soo Kim (ACC 2012)

 

Impact of Platelet Reactivity When On-treatment With Clopidogrel on Mortality, MI or Stent Thrombosis After PCI: A Collaborative Meta-Analysis of Individual Patient Data

      -Trial Results by Dr. Somjot Brar and Dr. George D. Dangas (ACC 2011)

 

INNOVATE PCI: Intravenous and Oral Elinogrel vs. Clopidogrel as a Novel Antiplatelet Therapy in Patients Undergoing Non-Urgent PCIs

      -Trial Results by Dr. Sunil Rao (ESC 2010)

ISAR-DESIRE: Intracoronary Stenting and Antithrombotic Regimen - Drug-Eluting Stents for In-Stent Restenosis

      -Clopidogrel vs. Placebo Among Patients with ST Elevation Myocardial Infarction (MI) Also Treated with Aspirin by Dr. A. Kastrati (European Society of Cardiology Congress 2004)

ISAR-REACT: Intracoronary Stenting and Antithrombotic Regimen - Rapid Early Action For Coronary Treatment

      -Evaluates Role of Abciximab in Reducing Postprocedure Ischemic Complications in Low-Risk Patients Pretreated with Clopidogrel who Undergo Coronary Stenting (ACC 2003)

ISAR-SWEET: Intracoronary Stenting and Antithrombotic Regimen - Is Abciximab a Superior Way to Eliminate Elevated Thrombotic Risk in Diabetics?

      -Trial Overview by Dr. Julinda Mehilli (AHA 2004)

 

PLATO: the PLATelet Inhibition and and patient Outcomes trial- Ticagrelor compared with Clopidogrel in Patients with Acute Coronary Syndromes

     -Trial Overview by Dr. Kenneth Mahaffey

      -Trial Overview by Dr. Lars Wallentin

      -Outcomes in Patients with a Planned Invasive Strategy by Dr. Christopher Cannon

 

PLATO PLATELET Substudy: Inhibitory Effects of Ticagrelor Compared to Clopidogrel on Platelet Function in Patients with Acute Coronary Syndromes

      -Study Overview by Dr. Robert F. Storey

PREMIER Registry: Prospective Registry Evaluating Outcomes After Myocardial Infarction: Events and Recovery Quality Improvement Registry

      -Discontinuation of clopidogrel associated with higher mortality following drug eluting stent implantation in STEMI, adds to concerns of BASKET Late

PRINCIPLE-TIMI 44: Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation - Thrombolysis In Myocardial Infarction (TIMI) 44

      -Trial Overview by Dr. Stephen D. Wiviott (2007)

 

RESET: A New Strategy for Discontinuation of Dual Antiplatelet Therapy: Real Safety and Efficacy of 3-Month Dual Antiplatelet Therapy Following Zotarolimus-Eluting Stent Implantation

      -Trial Overview by Dr. Myeong-Ki Hong (TCT 2012)

 

TRIGGER-PCI: Testing Platelet Reactivity in Patients Undergoing Elective Stent Replacement on Clopidogrel to Guide Alternative Therapy with Prasugrel

      -Primary Results by Dr. Dietmar Trenk (TCT 2011)

 

TRILOGY ACS: Prasugrel vs. Clopidogrel in Patients with Non-ST-Segment Elevation ACS Who Are Medically Managed After Coronary Angiography

      -Prasugrel versus clopidogrel for patients with unstable angina/NSTEMI who are medically managed without revascularization by Dr. Matthew Roe and Dr. Magnus Ohman (ESC 2012)

      -Trial Results by Dr. Stephen D. Wiviott et al. (TCT 2012, AHA 2012)

 

TRILOGY ACS Platelet Function Sub-study: First Large-Scale Platelet Function Evaluation in an Acute Coronary Syndromes Trial

      -Trial Overview by Dr. Paul Gurbel and Dr. Magnus Ohman (AHA 2012)

TRITON-TIMI 38: Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel - Thrombolysis In Myocardial Infarction (TIMI) 38

      -The Risk of CV Events for Patients Treated with Clopidogrel or Prasugrel in Combination with a Proton Pump Inhibitor: Results from the TRITON-TIMI 38 Trial by Dr. Michelle O'Donoghue, et al. (ESC 2009)

      -Trial Overview (AHA 2007)

WOEST: First Randomized Trial that Compares Two Different Regimens With and Without Aspirin in Patients on Oral Anticoagulant Therapy (OAC) Undergoing Coronary Stent Placement (PCI)

      -Trial Overview by Dr. JurriŽn ten Berg (ESC 2012)

(Return to Contents)

 Clopidogrel Pre-Treatment Studies

ARMYDA-5: Antiplatelet Therapy for Reduction of Myocardial Damage During Angioplasty Trial

      -Prospective, multicenter, randomized trial investigating influence on outcome of in-lab 600 mg clopidogrel loading vs 6-hour pre-PCI treatment - "ARMYDA-Preload" by Dr. Germano Di Sciascio (TCT 2007)

      -Trial Overview by Dr. Germano Di Sciascio and  Dr. Giuseppe Patti (ESC 2010)

Pretreatment with Thienopyridines

      -Emerging Data Regarding the Potential Benefits of Early Initiation of Clopidogrel Among ACS Patients by Dr. C. Michael Gibson

(Return to Contents)

 Clopidogrel Loading Dose Studies

CLOVIS-2: A Crossover Study of a High vs. Low Clopidogrel Loading Dose in Clopidogrel Resistant Patients
      -A Prospective, Randomized, Nested Case-Control Crossover Study of a High vs. Low Clopidogrel Loading Dose in Clopidogrel Resistant Patients With and Without the CYP2C19*2 Loss-of-Function Allele by Dr. Jean-Philippe Collet (TCT 2010)

 

Early Stent Thrombosis

      -Tailored Clopidogrel Loading Dose According to Platelet Reactivity Monitoring Decrease Early Stent Thrombosis by Dr. Laurent Bonello, et al.

Superiority of 600 mg of Clopidogrel as a Loading Dose

      -A MetaAnalysis by Dr. G. Biondi-Zoccai, et al. (SCAI 2007)

(Return to Contents)

 Platelet Physiology

Antiplatelet Resistance

      -What Does It Mean and What Should/Can We Do About It? by Dr. Dominick Angiolillo (CRT 2008)

Antiplatelet Therapy

      -Antiplatelet Therapy Use After Discharge Among Acute Myocardial Infarction Patients with In-hospital Bleeding by Dr. Tracy Y. Wang (2008)

Clopidogrel and Omeprazole Interaction Studies: Proton Pump Inhibitor Studies

      -Overview by Dr. Dominick Angiolillo

 

Clopidogrel Non-Responsiveness

      -Clinical Implications of Clopidogrel Non-Responsiveness by Dr. Dominick Angiolillo

Clopidogrel Response

      -Clopidogrel Response Variability and Resistance by Dr. Paul A. Gurbel

Drug-Eluting Stent

      -Impact of Platelet Reactivity Following Clopidogrel Administration on Drug-Eluting Stent Thrombosis by Dr. David Antoniucci

      -Clopidogrel Use and Long-term Clinical Outcomes After Drug-Eluting Stent Implantation by Dr. Eric Eisenstein, et al.

Dual Antiplatelet Treatment

      -Long-Term Outcomes in Patients Undergoing Coronary Stenting on Dual Oral Antiplatelet Treatment Requiring Oral Anticoagulant Therapy by Dr. R. Rossini, et al. (2008)

      -Prevention of Premature Discontinuation of Dual Antiplatelet Therapy in Patients with Coronary Artery Stents by Dr. Cindy L. Grines, et al. (2007)

SUNSET Registry

      -Clopidogrel Use and Death/MI After Stent Implantation in a Diabetic Population: Results from the SUNSET Registry by Dr. Somjot S. Brar, et al. (SCAI 2007)

(Return to Contents)

 Genomics

Clopidogrel Loading Dose Adjustment According to Platelet Reactivity Monitoring in Patients Carrying the 2C192* Loss-of-Function Polymorphism:

      -Overview by Dr. Laurent Bonello

 

Clopidogrel Platelet Reactivity Over Time in Patients Treated with PCI: Relationship with Gene Polymorphisms and Clinical Outcome

      -Overview by Gianluca Campo (CTR 2011)

 

CURE Genetic Substudy: Effects of CYP2C19 Genotypes on Clopidogrel Treatment in the CURE and ACTIVE Trials

      -Trial Overview by Dr. Guillaume Pare (ESC 2010)

 

 

Cytochrome P450 2C19 Polymorphism

      -Cytochrome P450 2C19 Polymorphism in Young Patients Treated with Clopidogrel After Myocardial Infarction: A Cohort Study by Dr. Jean-Philippe Collet, et al. (2008)

 

ELEVATE-TIMI 56: Escalating Clopidogrel by Involving a Genetic Strategy-TIMI 56

      -Trial Overview by Dr. Jessica Mega (AHA 2011)

 

PRO-GR: High-Dose Clopidogrel vs. Prasugrel in Clopidogrel Resistant Patients With and Without the CYP2C19*2 Loss-of-Function Allele

      -A Prospective, Randomized, Crossover Study of Maintenance High-Dose Clopidogrel vs. Prasugrel in Clopidogrel Resistant Patients With and Without the CYP2C19*2 Loss-of-Function Allele by Dr. Dimitrios Alexopoulos (TCT 2010)

 

RAPID GENE: A Prospective, Randomized Trial of Prasugrel vs. Clopidogrel in CYP2C19*2 Carriers Identified by Rapid Point-of-Care Genotyping

      -Trial Overview by Dr. Derek So (TCT 2011)

 

Relation Between CYP2C19 Genotype and Platelet Function in Ticagrelor Versus Clopidogrel Treated Patients: Results from the ONSET/OFFSET and RESPOND Studies

      -Overview by Dr. Paul A. Gurbel

 

RESET GENE: Pharmacodynamic Effects of Switching Therapy in PCI Patients with High on Treatment Platelet Reactivity and Genotype Variation: High Clopidogrel Dose Versus Prasugrel.

      -Study Overview by Dr. Gennaro Sardella (ACC 2012)

 

(Return to Contents)

Who Are We?    Slide Downloading Policy   Financial Disclosure    We Do Not Promote Off Label Product Use    Copyright    Source of Slides    Editorial Policy    Links Policy    Privacy Policy   Access    CME Programs

© 1999-2009 by Clinical Trial Results .org.  None of the materials on this website may be reproduced, modified, distributed, transmitted, republished, displayed, or performed unless prior written approval is obtained by Clinical Trial Results.  All such requests should be forwarded to Susan J. Marble at smarble@clinicaltrialresults.org. For further information please see the Policy section. Webmaster